ACAD Sale Disclosure
Schneyer Mark C. · SEC Form 4 · Filed Oct 30, 2026
Sale
Calculated transaction value
$69.34K
Schneyer Mark C. EVP, Chief Financial Officer
ACAD
Transaction date
Oct 30, 2026
Public filing date
Oct 30, 2026
Filing lag
Filed same day
ACAD daily price context
Close on/before transaction
$20.59
Oct 30, 2026
First close after public filing
$20.47
Nov 2, 2026
Return after filing · so far
+3.71%
Through Nov 6, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 3,321 shares @ $20.88
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001899977-26-000010
Filing cohort
Transactions in this filing
Showing 2 of 2
Trades
2
Issuers
1
Estimated value
$69.34K
Buys / sales
0 / 1
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Acadia Pharmaceuticals Inc ACAD Current | Sale | Oct 30, 2026 | $69.34K |
| Acadia Pharmaceuticals Inc ACAD | Award | Oct 15, 2026 | $0 |